Work

Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

Year: 2005

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.03.4082

Authors: David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jennifer A. Quinn, Jeremy N. Rich, James J. Vredenburgh, Annick Desjardins, Sri Guruangan, Michael Badruddoja, Jeanette M. Dowell, Terence Z. Wong, Xiao-Guang Zhao, Michael R. Zalutsky, Darell D. Bigner

Institutions: Duke University, Duke Medical Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Center for Research Resources

Awards: G460175554, G4946238614, SRC on Primary Tumors of the CNS, G758947967, G845704651

OpenAlex ID: W2135881288

FWCI: 7.37

Cites: 38

Cited by: 197

Related to: 10